Top Markets
#1 MON MON +2,757.44%
#2 $1 is all you need $1 is all you need +1,328.53%
#3 PYTHIA PYTHIA +46.60%
#4 eCash eCash +31.94%
#5 Siren Siren +23.75%
#6 SAFEcoin SAFEcoin +19.98%
#7 Janction Janction +18.96%
#8 PinGo PinGo +15.95%
#9 Velvet Velvet +15.57%
#10 Beldex Beldex +13.32%
Coin of the day
MON MON
設定
言語
日本
通貨
USD
テーマ
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
株式のランク #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
株価
$0.30780727
時価総額
$94.19M
変化（1日）
-0.19%
変化（1年）
-34.73%
国
FR
取引 Sensorion SA (ALSEN)

カテゴリー

Healthcare
Sensorion SA（ALSEN）のP/E比率
July 2026 時点のP/E比率 TTM -2.42
Sensorion SA の最新の財務報告および株価によると、現在の P/E (TTM) は -2.42 です。2023 年末時点での P/E は -2.60 でした。
Sensorion SA の P/E 比率の履歴（2011 〜 2026）
各年末のP/E比率
年 P/E比率 変化
2026 (TTM) -2.42 -65.24%
2024 -6.95 167.42%
2023 -2.60 104.30%
2022 -1.27 -87.45%
2021 -10.14 -0.11%
2020 -10.15 679.21%
2019 -1.30 40.12%
2018 -0.93 -67.76%
2017 -2.88 -34.75%
2016 -4.42 -48.61%
2015 -8.60 78.86%
2014 -4.81 -46.55%
2013 -9.00 -40.04%
2012 -15.00 -50.66%
2011 -30.41 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 11.47 -574.60%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -1,308.85%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 14.66 -706.91%
US
UCB SA UCB SA
UCB SA
UCB.BR
 31.95 -1,422.65%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 51.86 -2,246.81%
NL
P/E比率の読み方

株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。